Turn of the coin
A Drug Discovery News (DDN) article featuring commentary from Marco Silleni, discussing the challenges of autoimmune disorders. Silleni mentions the potential for extended therapy often means that regulatory authorities are much more focused on chronic toxicities and the requirement of long-term safety data. In addition, chronic autoimmunity diseases often mean lengthy trials and clinical monitoring, therefore the qualifications and skills of assessors are paramount.
Download Article